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ABSTRACT
In order to clarify the trnsciptional regul of the
NFKB2 gene (Iyt-10, NF-cBp100), we have char-
ized the structure and function of Its p er egions.
Based on the nuclotide sequence ofcDNA ckin and
the 5' flanking genomic region of the NFKB2 gene,
RT-PCR analysis in a number of human cell lines
demonstrated the presence of two alternative non-
coding first exons (la and lb). Two distinct promoter
regions, P1 and P2, were kientified upstream of each
exon, containing muMple sites of transcription initi-
ation, as shown by RNase protection analysis.
Sequence analysis of these regions showed a CAAT
box upstream of exon la and high G-C content regions
within both PI and P2. Consensus binding sites for
transcription factors, Including SP1, API and putative
NF-icB (KcB sites), were found upstream of each exon.
In particular, six icB sites were identified, all but one of
them capable of binding NF-cB complexes in vitro.
Transfection in HeLa cells of plasmids containing PI
and P2 sequences linked to a chloramphenicol acetyl-
transferase reporter gene indicated that both PI and P2
can act independently as promoters. Co-transfection
of NF-icB effector plasmids (NF-icBp52 and ReIA) with
a reporter gene linked to PI and P2 showed that the
NFKB2 promoter regions are regulated by NF-icB
factors. ReIA transactivates the NFKB2 promoter in a
dose-dependent manner, whereas NF-icBp52 acts as a
repressor, indicating that the NFKB2 gene may be
under the control of a negative feedback regulatory
circuit.
INTRODUCTION
The transcription factor NF-icB is a pleiotropic protein complex
which exerts its activity via the cis-acting icB DNA binding motif
present in a wide variety of cellular genes, including those
involved in the immune response and acute phase reactivity, as
well as viral genes such as those of human immunodeficiency
EMBL accession no. X83768
virus and other viruses (1-3). A number of structurally and
functionally heterogeneous NF-icB complexes have been identi-
fied. It is now evident that NF-icB activity is strictly dependent
upon protein-protein interactions among various NF-icB factors
and among these and inhibitory molecules (IKBs) which control
the subcellular (nuclear/cytoplasmic) localization of the active
complexes. In response to extracellular stimuli, including cyto-
kines, mitogens and viruses, the NF-icB complexes are released
from IBs and translocated to the nucleus (4-6). Among the
NF-icB transcription factors, the high structural homology
between the NFKB 1 (7-9) and NFKB2 proteins (10-13) allowed
the identification of a subfamily of NF-KB factors. Both proteins
are synthetized as precursor proteins (plO5 and plOO respectively)
containing: (i) an N-terminal DNA binding rel domain homolo-
gous to the one present in RelA (p65) (14,15), c-rel (16-18), RelB
(19,20), v-rel (21,22) and the product of the Drosophila dorsal
morphogen gene (23); (ii) a stretch of glycine residues proposed
as the site of proteolytic cleavage in NFKB1 protein; (iii) a
C-terminal domain containing ankyrin repeats (24), which has
also been found in the inhibitory proteins IicBa/MAD-3 (25),
IK13B/pp40 (26), IcBy (27,28), bcl-3 (29,30) and ECI-6 (31).
Regarding the function of the NFKB2 protein, recent data
indicate that the active form, NFKB2p52, derives from post-
translational processing of plOO, is localized in the nucleus and
binds DNA with an affinity for cB sequences which is different
from that ofNFKB 1 (32,33). NFKB2p52 is capable ofregulating
KB-dependent transcription activity when present in hetero-
dimers with RelA or when complexed with bcl-3, while it acts as
a negative transcriptional regulator in the form of a p52/p52
homodimer (12,33,34).
Transcription regulation of NF-icB genes, including NFKB2,
NFKB1 and IkcBc, may also be an important mechanism in
regulating NF-icB activity. Furthennore, a number of observa-
tions indicate that NF-icB activity is involved in the self-regula-
tion of various NF-icB coding genes, suggesting the presence of
inducible autoregulatory pathways within the NF-icB system
(35-40). ReLA, NFKB1 and the heterodimer RelA/NFKB1
transactivate the NFKB 1 promoter, indicating that NFKB 1 also
participates in its own regulation (35). Negative autoregulation of
c-rel and modulation of c-rel by v-rel has been shown in chicken
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Figure 1. Structure of the 5' flanking region of the NFKB2 gene. (A) Partial restriction map of the genomic BstXI-BstXI clone including the untranslated exons la
and lb. (B) Nucleotide sequence ofthe 5' flanking region ofthe NFKB2 gene. The italic letters correspond to the transcribed sequences; the arrows indicate the positions
of the transcription initiation sites according to the results shown in Figure 3, and 'O' indicates the major transcription initiation site upstream of exon la. The start of
exon lb corresponds to the first nucleotide of our longest cDNA NFKB2 clone (A. Neri, unpublished results) The CAAT box is boxed and the putative binding sites
for transcription factors are underlined. Restriction enzymes sites: Bs, BstXI; B, BamHI; R, EcoRI; S, SmaI; A, AccI; F, FnuH4.
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Figure 2. Alternative transcription of exons la and lb of the NFKB2 gene. RT-PCR analysis of RNA from different cell lines stimulated with PMA (50 ng/ml).
(A) Primers specific for exons la and 2; (B) primers specific for exons lb and 2. M, Markers; NC, negative control. The lower parts of the panels show Southern blot
analysis using probes specific for exons la and lb. The larger and faint PCR-amplified product detectable in (B) could represent non-specific PCR product.
cells (36,37), while the murine c-rel promoter is transactivated by
the c-rel protein in B cells (38). The genes encoding for the
inhibitory proteins are also regulated by NF-icB activity, as shown
by the presence of a KB motif within the promoter region of the
IcBa gene, which is specifically controlled by RelA (39,40).
These observations indicate that characterization of the regula-
tory/promoter region of other NF-iB genes, particularly of those
that are inducible, could improve our understanding of the overall
regulatory network of the NF-icB system. The present paper
reports a structural and functional analysis of the NFKB2 gene
promoter region and shows that RelA enhances the activity of the
NFKB2 promoters, while NFKB2p52 is capable of negatively
regulating its own promoter.
MATERIALS AND METHODS
Cell lines
The lymphoblastoid cell line CB33, the pre-B cell line 697 and the
Jurkat T cell line were maint in RPMI 1640 containing
glutamine, antibiotics and 10% heat-inactivated fetal calf serum
(FCS). The HeLa cell line was grown in Dulbecco's modified
Eagle's medium supplemented with 10% FCS. In some experi-
ments the cells were teated for 12 h with 50 ng/ml phorbol
myristate acetate (PMA) (Sigma, St Louis, MO).
Genomic cloning
Genomic clones representative ofthe NFKB2 locus were isolated
from a genomic library constructed by cloning partially Sau3A-
digested human placental DNA into the EMBL3 phage vector
(Stratagene, La Jolla, CA). Screening was performed by plaque
hybdization using the full-length NFKB2 cDNA clone as probe
(10), 32P-labelled by the random priming method (41). Isolated
plaques were grown and phage DNA obtained according to
established procedures (42). Inserts were analysed by restriction
enzyme mapping and then subcloned into plasmid vectorpGEM3
(Promega, Madison, WI) for further analysis.
DNA sequencing
DNA sequencing was performed on restriction fragments cloned
into the pGEM3 plasmid by dideoxy chain termination analysis
using the Sequenase sequencing kit (USB, Cleveland, OH).
cDNA amplification
First-strand cDNA was synthesized in 20 p1 reactions containing
1 ig total RNA extracted from various human cell lines, 1 mM
each dNTP, 0.1 mM DTT, 5x reverse-transcription buffer, 1 U
RNasin (Promega), 200 U Super-Script reverse transcriptase
(Gibco-BRL, Gaithersburg, MD) and 20 pM primer (5'-TAG-
CAACTCTCCATGTCTCT-3') specific for the second exon of
the NFKB2 gene. The reaction mixes were incubated for 1 h at
370C and stored at -200C. PCR amplifications were performed
by diluting 10 p1 of first-strand cDNA from each cell line into 50
gl mixtures containing 200mM each dNTP, 50mM KCl, 10mM
Tris, pH 8.3, 1.5 mM MgCl2, 0.01% (w/v) gelatin, 2.5 U Taq
polymerase (Boehringer Mannheim, Germany) and 20 pM each
specific primer. As 3' primer an internal primer specific for the
second exon was used (5'-GCTCTGTCTAGTGGCTCC-3'). The
5' primers were the following: 5'-AGAGCAGCAGCTGCACA-
CAG-3' (specific for exon la); 5'-AACTCCGGATCTCGCTCTC
C-3' (specific for exon lb). Amplification reactions (30 cycles)
were performed using a Perkin-Elmer-Cetus (Norwalk, CT) DNA
thermal cycler under the following conditions: denaturation at
94°C for 15 s, annealing at 65°C for 30 s and extension at 720C
for 30 s. The amplified fragments (153 bp for exons la/2, 116 bp
for exons lb/2) were resolved in agarose gel and further analyzed
by Southern blot using specific internal probes.
RNA extraction and RNase protection analysis
RNA was extracted using the guanidine isothiocyanate method.
The RNase protection assay was performed as previously
described (43). The EcoRI-PvuII (217 bp) and the AccI-BglII
(256 bp) fragments, respectively containing parts of exons la and
lb and their 5' regions, were cut from the genomic clone
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Figure 3. Determination of the transcription initiation sites of the NFKB2 gene
by RNase protection analysis. TotalRNA (30 tg) from HeLa cells unstimulated
(lane 1) and stimulated with 50 ng/ml PMA (lane 2) was analysed using
riboprobes specific for exon la (A) and exon lb (B). The riboprobes are
schematically described at the bottom of the figure. Mouse RNA (lane 3) and
tRNA (lane 4) were used as negative controls. The size of the protected
fragments was determined from the sequencing ladder in the middle of the
figure, which represents the sequence of the BstXI 2.1 kb fragment using as
sequencing primer a reverse primer specific for the 3' border of exon lb (Fig.
1, positions 1192-1211). P, probes.
BstX1-BstXI fragment of the NFKB2 gene (see below), cloned
into pGEM3 vector (Promega) and transcribed using SP6 RNA
polymerase. The antisense 32P-labelled riboprobes were hybrid-
ized with 30 ,ug total RNA for 16 h at 65°C, followed by RNase
digestion. The protected fragments were resolved in 6% denatur-
ing polyacrylamide gels and analysed by autoradiography.
Expression vectors and plasmid construction
The entire 5' region of the NFKB2 gene containing exons la and
lb and part of the second exon (a BstXI-BstXI fragment of 2113
bp, shown in Figure 1, originally cloned in the HincH site of
0.17
Figure 4. Functional analysis of the NFKB2 promoters. A series of deleted
plasmids was prepared from the pLyt-2.1 construct using the indicated
restriction enzyme sites and tested for their CAT activity in HeLa cells (0.5
pmol). The putative NF-iB binding sites are indicated by filled squares, the
CAAT consensus sequence by an open circle, the API-like sites by filled circles
and the SPI box by small bars. The relative CAT activity and the nomenclature
of the plasmids are indicated on the right of the figure. The results are
representative of at least three experiments and are normalized for transfection
efficiency.
plasmid pGEM3) was inserted in the HindIII and XbaI sites of the
pCAT-basic plasmid (Promega). Several deletions in the cloned
fragment generated a series of plasmids whose restriction
mapping is presented in Figure 4 in the context of the analysis of
reporter constructs. The plasmid pLI-0.3 was constructed by
cloning a PCR-amplified product of 318 bp from -159 to +159
into the same expression vector.
The full-length cDNA of RelA (obtained from C. A. Rosen)
was inserted in the pCEP4 expression vector (Invitrogen, San
Diego, CA) at the PvuII site. The same expression vector was
used for cloning the EcoRI-XhoI fragment of NFKB2 cDNA,
containing the rel domain and lacking the ankyrin domain (10).
Transfection and chloramphenicol acetyltransferase
(CAT) assay
HeLa cells were plated at 3 x 105/100 mm Petri dish 24 h prior to
the experiment. The plasmids were transfected at the doses
indicated in the legends to the figures using a modified CaPO4
precipitation procedure (42). Approximately 48 h after transfection
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Figure 5. PMA stimulation of the NFKB2 promoters. The plasmids (0.5 pmol) indicated at the bottom of the figure (see also Fig. 4) were transfected into HeLa cells
with orwithoutPMA stimulation (50 ng/ml for 12 h). The relative CAT activities are referred to the longestconstruct, pLyt-2.1, withoutPMA sfimulation. The numbers
above the bars indicate fold transactivation versus the basal value of the plasmid. The results are the mean values of at least three experimnts and are normalized for
transfection efficiency.
the cells were harvested and lysed by several rounds of
freeze-thaw in 25 mM Tris, pH 7.5. The transfections in HeLa
cells also includedO.5 pmol CMV-0-gal plasmid, which was used
as an internal control to nonnalize transfection efficiency. When
NF-iB2p52 and p65 expressing vectors were co-transfected with
NFKB2-CAT plasmids the values of acetylation were referred to
the protein content, because of the interference of RelA protein
with the promoterdriving the P-gal gene. CAT and ,B-gal activities
were determined as described by Gorman et al. (44) using 20-50
p1 cell extracts. CAT activity was expressed as a percentage ofthe
acetylated form of chloramphenicol as compared with the total
number of counts in the acetylated and non-acelylated forms.
Electrophoretic mobility shift asys (EMSA)
The prepation of nuclear extracts has been previously described
(45), as well as the EMSA analysis (46). The six KB oligonucleo-
tide probes include each KB site and the surrounding 5 nt at the 5'
and 3' borders. For antibody-induced supershift assays 0.5 p1
undiluted antiserum was incubated with 2-5 pg nuclear extract on
ice for 30 min, followed by 20 min incubation with labelled probes.
RESULTS
Characterization of the NFKB2 promoter regions
In our previous report (47) we described the cloning and
intron/exon organization of the NFKB2 gene. One of the clones
isolated from a genomic library constructed from human placental
DNA (the BstXI-BstXI subclone) was shown to contain 2113 bp
ofDNA (Fig. IA) including two alternative first exons (la and lb)
identified in distinct cDNA clones (10,12). To confirm the
alternative tanscription of exons la and lb, RT-PCR analysis was
performed in different cell lines. Figure 2 shows that two distinct
PCR-amplified fragments can be obtained using a combination of
primers specific for exon 2 and exon la or lb. These fragmnts
represented the linkage between exons la/2 (Fig. 2A) and exons
lb/2 (Fig. 2B), as demonsaed by their length, hybridization to
specific probes and direct DNA sequencing (data not shown).
Moreover, cDNA amplification using exon la/lb-specific primers
did not generate fragments containing these sequences (data not
shown). Thus these data indicate tgat the two first exons are
alternatively included in distinct mRNA species.
In order to map the region containing the initiation of
transcription site(s) we performed RNase protection analysis,
using riboprobes spanning parts of exons la and lb and their 5'
flanking regions (see Fig. 3A and B). RNA was obtained from
HeLa cells under basal conditions and after treatment with PMA,
which induces NFKB2 gene transcription (12). PMA stimulation
allowed the detection of exon la-initiated transcripts, which are
expressed at a very low level or are totally absent under basal
conditions (see Fig. 3A, lane 1). One majortranscription initiation
site was identified in the 5' region flanking exon la (Fig. LA) and
this was arbitrarily designated site 0 in relation to the rest of the
sequence. Five other minor start sites were localized at approxi-
mate positions -45, -41, -23, -16 and +5. Multiple start sites were
also responsible for transcription through exon lb; within this
region two major start points were localized at positions +1074
and +1079 and minor start points were identified at positions
+1105, +1111 and +1130. The sequence analysis of the BstXI-
BstXl clone (Fig. 1B) showed a CAAT box located 144 bp
upstream of exon la and CpG islands upstream of both exons
(75% G+C-rich within 100 bp). A number of potential binding
sites for transcription factors were identified in this region (Fig.
1B). Five SPI consensus sequences were found, one 229 bp
upstream ofexon la and four interspersed among the transcription
start sites upstream ofexon lb. Furthennore, the 5' region flanldng
exon la also contains three API-like elements. Interestingly, six
NF-iB consensus sequences were identified (icB 1-6): KB3 has
been found in TNFac and vimentin promoters (48-50); iB5 is
present in the TNFO and also the NFKB1 promoter (35,51-52);
KB6 is common to various viruses, such as HIV, SV40,CMV and
adenovirus (53-56). The remaining xB sites (1, 2 and 4) are
slightly different from the icB motifs previously described in the
regulatory region of other genes.
Functional analysis of the NFKB2 promoter regions
In order to demonstrate that the 5' region of the NFKB2 gene
contains a functional promoter a series of chimeric plasmids
containing various segments of this region linked upstram ofthe
CAT reporter gene was prepared and transfected into HeLa cells
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Figure 6. Characterization of the functional activity of the KB sites of the NFKB2 gene promoter regions. The six putative KB sites were used as probes in EMSA
with HeLa cell nuclear extracts. The arrow indicates the supershifted bands; I and 2 indicate the two major NF-icB complexes; the asterisk indicates a possible
homodimeric form of p52.
(Fig. 4). The longest construct (pLYT-2. 1, a BstXI-BstXI
fragment containing exons la, lb and the untranslated part ofexon
2) displayed a promoter activity which is -35-fold higher than the
parental CAT vector (pCAT basic). Since the first two exons are
alternatively transcribed, we analysed the 5' regions spanning exon
la and lb separately. The activity of pL1-0.9 was 3-fold higher than
that ofthe pLYT-2. 1 construct, whereas the activity ofpL2-1.2 was
similar to pLYT-2.1. This indicates that two distinct regions (P1
and P2) can act independenfly as promoters with comparable
strength. To further characterize the active promoter regions a
series of 5' deletions was performed in the constructs pLl-0.9 and
pL2-1.2. As shown in Figure 4, the sequences from -159 to -101
are essential for transcriptional activity of P1, as shown by the
dramatic reduction (>50-fold) observed when this fragment is
deleted (see pLl-0.3 versus pLl-0.25). The smallest region
sufficient for P2 promoter activity (20-fold above basal level) can
be identified within the StyI-FnuH4 fragment (pL2-0.29). The
evidence that constructs pL2-0.37, pL2-0.6 and pL2-1.2 have
higher activity than pL2-0.29 indicates that these regions may
contain positive regulatory sequences in addition to promoter
sequences. The same sequences did not display any activity when
used in inverted orientation. PMA treatment has a slight effect in
inducing P1 and P2 CAT activity, even if P1 seems to be the
preferential target for such an induction (Fig. 5). The pLl-0.3
construct, which contains two kB sites but no APi-like sequences,
is still induced by PMA treatment, suggesting that the KB sites are
responsible for PMA induction.
Regulation of NFKB2 promoters by RelA and NFKB2
proteins
The presence of NF-KB consensus sequences in the promoter
region of the NFKB2 gene prompted us to analyse both the
capability of the various KB sites to bind NF-icB complexes in
vivo and the effect of overexpression of RelA and/or NFKB2
proteins on the activity of the promoters. Figure 6 shows the
EMSAs performed with nuclear extracts from PMA-stimulated
HeLa cells and double-stranded nucleotides encompassing the
sequences of all six KB sites. NF-KB complexes were detectable
when KB 1-3, 5 and 6 were used as probes, indicating that the
non-canonical KB1 and 1cB5 are also functionally active in
binding NF-icB complexes. Using specific antibodies we ob-
served that all of the active KB sites are capable of binding
complexes containing RelA; in addition, iBl-3 and 6 are also
able to bind complexes containing NFKB2pS2. Similar results
were obtained with Jurkat T cells (data not shown).
To investigate the effect of RelA and NFKB2pS2 on the
NFKB2 promoter, transient co-transfection experiments were
carried out in HeLa cells using 0.5 pmol pLYT-2. 1 CAT construct
(see Fig. 4) as a target for the RelA and/or NFKB2pS2 products
expressed under control of the CMV promoter. As demonstrated
by Western blot analysis (data not shown), the levels of RelA
expression in these experiments and in those represented in
Figure 8 were similar when transfected alone or in combination
with NFKB2pS2. As shown in Figure 7A, RelA is capable of
transactivating the promoter of the NFKB2 gene in a dose-
dependent manner, indicating that RelA may be involved in the
positive regulation of NFKB2 expression. Using the same
experimental approach we analysed the activity ofNFKB2 on its
own promoter (Fig. 7B). A progressive dose-dependent
repression was achieved, reaching 70% at high (2 pmol) inputs of
effector. NFKB2 was also capable of strongly inhibiting the
transactivation activity of RelA on the NFKB2 promoter (Fig.
7C). These data indicate that NFKB2 pS2 can negatively control
the activity of its own promoter.
We analysed further the activity of the RelA and NFKB2pS2
proteins on P1 and P2 separately (Fig. 8). pL1-0.9, which contains
P1 and its 5' flanking region, is transactivated by RelA (Fig. 8B)
at a level comparable with the value observed in the construct
pLyt-2. 1, representative of the entire promoter region. Converse-
ly, NFKB2pS2 does not significantly reduce either the activity of
the P1 promoter (Fig. 8A) or the activity ofRelA on P1 (Fig. 8B).
We found similar results when the upstream iB site (pLl-0.53)
and the API and SPI sites (pLl-0.3) were deleted. The P2
promoter region (pL2-1.2) is transactivated by RelA at a similar
level to P1, but is negatively regulated by NFKB2 (-3-fold
reduction with respect to the basal value). Deletion of the 600 bp
upstream sequence (pL2-0.6) slightly reduces the activity of
RelA, which is even more reduced in pL2-0.37 (only -2-fold
induction) when KB5, which is able to bind RelA-containing
complexes, is deleted.
DISCUSSION
This study reports the identification and initial characterization of
the NFKB2 promoter regions and provides evidence for the
*06d *w,
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Figure 7. Activity of the RelA andNFKB2 products on the NFKB2 promoters.
HeLa cells were co-transfected with 0.5 pmol NFKB2 promoter CAT plasmid
pLyt-2.1 plus (A) increasing amounts ofpCMV-RelA, (B) increasing amounts
of pCMV-NFKB2p52 or (C) 1 pmol RelA and increasing amounts of
pCMV-NFKB2p52. The values of relative CAT activity are referred to the
activity of the NFKB2 promoter in the absence of exogenous factors. Each
column represents the mean of three or more independent experiments after
normalization to the protein concentration of cellular extracts.
involvement of the NFKB2 protein in its own regulation. These
results have implications for the mechanisms regulating NFKB2
expression and, in general, for the mechanism regulating overall
NF-KB activity.
In a previous paper (47) we showed that two non-coding exons
are present in the 5' region of the NFKB2 locus. The results herein
indicate that exons la and lb are alternatively transcribed,
generating two species ofmRNA transcripts of similar length that,
although differing in their 5' sequences, maintain the same coding
sequences. Furthermore, our results indicate that transcription of
these two exons is under the control of two distinct promoters,
which can be differentially regulated, based on several observa-
tions. First, sequence analysis revealed that although both promoter
regions have typical features of promoters containing multiple
transcription initiation sites surrounded by GC-rich regions (75%),
they differ in the fact that P1 has a CAAT box and no TATA box.
Although the influence of CAAT sequences on promoter activity
has not been clearly defined as yet, a similar arrangement has been
found in other human genes, such as the genes encoding interferon
regulatory factors 1 and 2 (56), and may have regulatory
significance. Secondly, P1 and P2 contain distinct sets of putative
binding sites for tanscription factors: APi-like binding sites
present only in PI and distinct iB sites in PI and P2. Finally, P1 and
P2 are differentially regulated by PMA, which acts preferentially
on P1, and by the NFKBp52 protin, which negatively controls P2.
Further studies are needed to determine whether P1 and P2 are
differentially regulated in different tissues, as is the case, for
instance, for the c-fgr gene (58), or in different stages of cell
differentiation, as has been shown for the p53 gene (59).
These features of the NFKB2 promoter regions distinguish the
NFKB2 gene from the NF-icB and IKB genes whose promoter
regions have been characterized so far, namely NFKB 1 (35),
murine and avian c-rel (36,38), RelA (60), IKBza (40) and ECI-6
(31). Conversely, the promoter regions of the NFKB2 gene are
similar to those of other NF-KB and lIB genes (31,35,36,38,40),
in that they contain several functional KB sites, supporting the
notion that the NF-icB transcription factor represents a highly
autoregulated system. In particular, our results show that the
NFKB2 gene can be positively regulated by ReLA, as well as
negatively by itself. These findings are consistent with recent
studies (33) demonstrating that NFKB2p52 has no intrinsic
transactivation capability and that its homodimeric form can
repress the transactivating activity ofReIA. It has been shown that
the diversity ofthe sequences ofthe KB sites reflects apreferential
affinity for different NF-KB subunits (3). We observed that the P2
promoter is the target forNFKB2p52 negative autoregulation and
the KB6 site is probably responsible for this regulatory mechan-
ism. Further studies should aim to understand the activity of other
members of the NF-KB family on the NFKB2 promoter and to
verify whether the same pattern ofresponse is present in different
cells or under different stimuli. In fact, a recent paper (61)
reporting the characterization of the NFKB2 promoter showed
that a positive autoregulation is exerted by the NFKB2 protein on
P1 in cells stimulated with PMA, while in the absence of NF-KB
activity a mechanism of repression is mediated by KB sites
through a repressor protein termed Rep-KB.
Finally, it is possible that the NF-KB autoregulatory mechanism
may be critical to maintain a physiological level of NF-iB
function in the presence of a multitude of activating stimuli and
that disruption of this mechanism may be involved in tumouri-
genesis. In fact, it is known that the NFKB2 locus is involved in
lymphoma-associated chromosomal rearrangements (10,62,63),
which lead to truncations within the ankyrin domain and the
consequent production of abnormal, constitutively active rel-
containing proteins.
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